secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0000950170-25-018419
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS
--------------------------------------------------------------------------------

- License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.
- Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.
- Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.
- Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.
- Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/0000950170-25-018419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/tivc-20250210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-018419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer